natgillin/translations-raw huggingface dataset:
EMEND og naturlægemidler med perikon (Hypericum perforatum) bør ikke administreres samtidigt.
John’ s Wort (Hypericum perforatum) is not recommended.
4. 5).
Concomitant administration of EMEND with active substances that inhibit CYP3A4 activity (e. g. ritonavir, ketoconazole, clarithromycin, telithromycin) should be approached cautiously, as the combination results in increased plasma concentrations of aprepitant (see section 4.5).
EMEND indeholder saccharose.
EMEND contains sucrose.
Patienter med sjælden, medfødt fructoseintolerans, glucose - galactosemalabsorption eller sukrase- isomaltasemangel bør ikke anvende denne medicin.
Patients with rare hereditary problems of fructose intolerance, glucose- galactose malabsorption or sucrase-isomaltase insufficiency should not take this medicine.
Aprepitant er et substrat og en dosiafhængig hæmmer af CYP3A4.
Aprepitant is a substrate and a dose-dependent inhibitor of CYP3A4.
Under behandling forårsager 40 mg aprepitantdosen, der anbefales til PONV, en svag hæmning af CYP3A4.
During treatment, the single 40 mg dose of aprepitant recommended for PONV results in a weak inhibition of CYP3A4.
Under behandling mod kvalme og opkastning i forbindelse med kemoterapi (CINV) er 3- dages behandlingsregimet med 125 mg/ 80 mg aprepitant en moderat hæmmer af CYP3A4.
During treatment for chemotherapy induced nausea and vomiting (CINV), the 3-day 125 mg/ 80 mg regimen of aprepitant is a moderate inhibitor of CYP3A4.
Induktionseffekten af en enkelt 40 mg dosis aprepitant er ikke undersøgt, men det er ikke sandsynligt, at en enkelt 40 mg dosis vil forårsage klinisk relevant induktion.
The effects of induction by a single 40 mg dose of aprepitant have not been studied, but it is unlikely that a 40 mg single dose will cause any clinically relevant induction.
Efter afsluttet behandling med 3 - dages CINV- regimet forårsager aprepitant en forbigående moderat induktion af CYP2C9 og en forbigående mild induktion af CYP3A4 samt glukuronisering.
After the end of treatment with the 3-day CINV regimen, aprepitant causes a transient moderate induction of CYP2C9 and a transient mild induction of CYP3A4 and glucuronidation.
For yderligere information om potentiel interaktion for aprepitant ved højere og multiple doser se venligst Produktresuméet for EMEND 80 mg hårde kapsler og EMEND 125 mg hårde kapsler.
For further information on interaction potential of aprepitant at higher and multiple doses, please refer to the Summary of Product Characteristics for EMEND 80 mg hard capsules and EMEND 125 mg hard capsules.
Som en svag hæmmer af CYP3A4 kan aprepitant (40 mg) øge plasmakoncentrationen af samtidigt oralt administrerede aktive substanser, som metaboliseres gennem CYP3A4.
Effect of CYP3A4 inhibition by aprepitant on the pharmacokinetics of other active substances As a weak inhibitor of CYP3A4, aprepitant (40 mg) can increase plasma concentrations of orally co-administered active substances that are metabolised through CYP3A4.
Virkningen af aprepitant på plasmakoncentrationen af intravenøst administrerede CYP3A4- substrater forventes at være mindre.
The area under the curve (AUC) of orally administered CYP3A4 substrates may increase up to approximately 1.5-fold after a single 40 mg dose of aprepitant; the effect of aprepitant on the plasma concentrations of intravenously administered CYP3A4 substrates is expected to be smaller.
3 EMEND 40 mg bør anvendes med forsigtighed til patienter, der får pimozid, terfenadin, astemizol, cisaprid eller ergotalkaloidderivater.
3 EMEND 40 mg should be used with caution in patients receiving pimozide, terfenadine, astemizole, cisapride, or ergot alkaloid derivatives.
Kortikosteroider:
Corticosteroids:
Når en enkelt dosis på 40 mg aprepitant blev administreret sammen med en enkelt oral dosis dexamethason 20 mg, forhøjedes AUC for dexamethason 1, 45 gange.
A single 40 mg dose of aprepitant, when co-administered with a single oral dose of dexamethasone 20 mg, increased the AUC of dexamethasone by 1.45-fold.
Selvom samtidig administration af methylprednisolon med en enkelt 40 mg dosis aprepitant ikke er undersøgt, forårsager en enkelt 40 mg dosis aprepitant en svag hæmning af CYP3A4, og det forventes ikke at ændre methylprednisolons plasmakoncentration i klinisk signifikant grad.
Although the concomitant administration of methylprednisolone with the single 40 mg dose of aprepitant has not been studied, a single 40 mg dose of aprepitant produces a weak inhibition of CYP3A4 and it is not expected to alter the plasma concentrations of methylprednisolone to a clinically significant degree.
Ved samtidig administration af en enkelt dosis aprepitant 40 mg og en enkelt oral dosis midazolam 2 mg øgedes AUC for oralt administreret midazolam 1, 2 gange; denne effekt blev ikke anset for at være klinisk signifikant.
The AUC of orally administrated midazolam increased by 1.2-fold when a single dose of 40 mg aprepitant was co-administered with a single oral dose of 2 mg midazolam; this effect was not considered clinically important.
Orale antikonceptiva:
Oral contraceptives:
Virkningen af en enkelt 40 mg dosis aprepitant på orale antikonceptiva er ukendt.
The effect of a single 40 mg dose of aprepitant on oral contraceptives is unknown.
Med højere og multiple doser aprepitant kan effekten af hormonelle antikonceptiva være nedsat under selve behandlingen og i 28 dage efter behandling.
With higher dose and multiple doses of aprepitant, the efficacy of hormonal contraceptives may be reduced during and for 28 days after administration.
Ved en enkelt 40 mg aprepitant- dosis anses det ikke for nødvendigt at tage særlige forholdsregler.
For the single 40 mg aprepitant dose, no special precautions are considered necessary.
5- HT3 antagonister:
5-HT3 antagonists:
Aprepitant ser ikke ud til at interagere med P- glykoproteintransportstoffet, som manglen på interaktion mellem aprepitant og digoxin antyder.
Aprepitant does not seem to interact with the P-glycoprotein transporter, as suggested by the lack of interaction of aprepitant with digoxin.
Andre aktive substansers virkning på aprepitants farmakokinetik CYP3A4- hæmmere Samtidig administration af EMEND og aktive substanser, som hæmmer CYP3A4- aktivitet (eks. ritonavir, ketoconazol, clarithromycin, telithromycin), bør kun ske med stor forsigtighed, idet kombinationen resulterer i forhøjede plasmakoncentrationer af aprepitant.
Effect of other active substances on the pharmacokinetics of aprepitant CYP3A4 inhibitors Concomitant administration of EMEND with active substances that inhibit CYP3A4 activity (e. g., ritonavir, ketoconazole, clarithromycin, telithromycin) should be approached cautiously, as the combination results in increased plasma concentrations of aprepitant.
CYP3A4- inducere Samtidig administration af EMEND og aktive substanser, som er stærke inducere af CYP3A4- aktivitet (eks. rifampicin, fenytoin, carbamazepin, phenobarbital), bør undgås, idet kombinationen resulterer i reducerede plasmakoncentrationer af aprepitant.
CYP3A4 inducers Concomitant administration of EMEND with active substances that strongly induce CYP3A4 activity (e. g. rifampicin, phenytoin, carbamazepine, phenobarbital) should be avoided as the combination results in reductions of the plasma concentrations of aprepitant that may result in decreased efficacy.
Dette kan nedsætte virkningen.
Concomitant administration of EMEND with herbal preparations containing St.
3 gange.
When a single 125 mg dose of aprepitant was administered on Day 5 of a 10-day regimen of 400 mg/ day of ketoconazole, a strong CYP3A4 inhibitor, the AUC of aprepitant increased approximately 5-fold and the mean terminal half-life of aprepitant increased approximately 3-fold.
Når en enkelt 375 mg dosis aprepitant blev administreret på dag 9 i et 14- dages behandlingsregime med 600 mg/ dag rifampicin, der er en stærk CYP3A4- inducer, faldt AUC for aprepitant med 91% og gennemsnitshalveringstiden faldt med 68%.
When a single 375 mg dose of aprepitant was administered on Day 9 of a 14-day regimen of 600 mg/ day of rifampicin, a strong CYP3A4 inducer, the AUC of aprepitant decreased 91% and the mean terminal half-life decreased 68%.
5. 3).
In animal studies there was no indication of direct or indirect harmful effects with respect to pregnancy, embryonal/ foetal development, parturition or postnatal development (see section 5.3).
Aprepitant udskilles i mælken hos diegivende rotter.
4 Aprepitant is excreted in the milk of lactating rats.
Derfor bør man ikke amme under behandling med EMEND.
It is not known whether aprepitant is excreted in human milk; therefore, breast-feeding is not recommended during treatment with EMEND.
Der er ikke udført undersøgelser af EMENDs virkning på evnen til at køre bil og betjene maskiner.
No studies on the effects of EMEND on the ability to drive and use machines have been performed.
4. 8).
However, when driving vehicles or operating machines, it should be taken into account that dizziness and fatigue have been reported after taking EMEND (see section 4.8).
4. 900 personer.
The safety profile of aprepitant was evaluated in approximately 4,900 individuals.
6% af patienterne i behandling med 4 mg ondansetron i. v.
Adverse reactions considered as drug-related by the investigator were reported in approximately 4% of patients treated with 40 mg aprepitant compared with approximately 6% of patients treated with 4 mg ondansetron IV.
I kontrollerede kliniske undersøgelser af patienter, der fik generel anæstesi, fik 564 patienter 40 mg aprepitant oralt og 538 patienter fik 4 mg ondansetron i. v.
In controlled clinical studies in patients receiving general anesthesia, 564 patients were administered 40 mg aprepitant orally and 538 patients were administered 4 mg ondansetron IV.
Forhøjet ALAT.
The most common adverse reaction reported at a greater incidence in patients treated with aprepitant (1.1%) than with ondansetron (1.0%) was ALT increased.
Følgende bivirkninger blev observeret hos de patienter, der fik behandling med aprepitant og med en højere incidens end hos patienterne i behandling med ondansetron:
The following adverse reactions were observed in patients treated with aprepitant and at a greater incidence than with ondansetron:
Frekvenser defineres som; Meget almindelig (≥ 1/ 10) Almindelig (≥ 1/ 100 til < 1/ 10) Ikke almindelig (≥ 1/ 1. 000 til < 1/ 100) Sjælden (≥ 1/ 10. 000 til < 1/ 1. 000) Meget sjælden (< 1/ 10. 000), ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
Frequencies are defined as: very common (≥ 1/ 10); common (≥ 1/ 100 to < 1/ 10); uncommon (≥ 1/ 1,000 to < 1/ 100); rare (≥ 1/ 10,000 to < 1/ 1,000) and very rare (< 1/ 10,000), not known (cannot be estimated from the available data).
Hjerte Nervesystemet Øjne Luftveje, thorax og mediasti - num
Cardiac disorders Nervous system disorders Eye disorders Respiratory, thoracic and mediastinal disorders
Bradykardi Dysartri, hypoæstesi, sensoriske forstyrrelser Myosis, nedsat synsskarphed Dyspnø, hvæsende vejrtrækning
Bradycardia dysarthria, hypoaesthesia, sensory disturbance miosis, visual acuity reduced dyspnoea, wheezing
Ikke almindelig Ikke almindelig Ikke almindelig Ikke almindelig
uncommon uncommon uncommon uncommon
Smerter i øvre del af abdomen, anormale tarmlyde, mundtørhed, kvalme, mavegener
abdominal pain upper, bowel sounds abnormal, dry mouth, nausea, stomach discomfort
Et tilfælde af konstipation, og et tilfælde af subileus.
In addition, two serious reactions were reported in clinical studies in postoperative nausea and vomiting (PONV) in patients taking a higher dose of aprepitant: one case of constipation, and one case of sub-ileus.
Mavesmerter, syrereflux, acne, øget alkalisk fosfatase, anæmi, anoreksi, angst,
Additional adverse reactions were observed in patients treated with the aprepitant (125 mg/ 80 mg) regimen for chemotherapy induced nausea and vomiting and at a greater incidence than with standard therapy: abdominal pain, acid reflux, acne, alkaline phosphatase increased, anaemia, anorexia, anxiety, AST increased, asthaenia/ fatigue, candidiasis, chest discomfort, cognitive disorder, conjunctivitis, constipation, cough, diarrhoea, disorientation, dizziness, dream abnormality, dysgeusia, dyspepsia, dysuria, enterocolitis, epigastric discomfort, eructation, euphoria, febrile neutropenia, flatulence, flushing, gastroesophageal reflux disease, headache, hiccups, hot flush, hyperglycaemia, hyperhidrosis, hyponatraemia, lethargy, microscopic haematuria, muscle cramp, myalgia, nausea*, obstipation, oedema, oily skin, perforating duodenal ulcer, pharyngitis, photosensitivity, pollakiuria,
* Kvalme og opkastning var effektparametre de første 5 dage efter kemoterapibehandling og først derefter indberettet som bivirkninger.
5 polydipsia, polyuria, postnasal drip, pruritus, rash, skin lesion, sneezing, staphylococcal infection, stomatitis, thirst, throat irritation, tinnitus, vomiting*, weight decreased, weight gain. *Nausea and vomiting were efficacy parameters in the first 5 days of post-chemotherapy treatment and were reported as reactions only thereafter.
Der er rapporteret om ét tilfælde af Stevens- Johnsons syndrom som en alvorlig hændelse hos en patient, som fik aprepitant sammen med cancerkemoterapi.
One case of Stevens-Johnson syndrome was reported as a serious adverse event in a patient receiving aprepitant with cancer chemotherapy.
Der er hos en patient, som fik aprepitant i en non- CINV/ non- PONV- undersøgelse, rapporteret om ét tilfælde af angioneurotisk ødem og urticaria som en alvorlig hændelse.
One case of angioedema and urticaria was reported as a serious adverse event in a patient receiving aprepitant in a non-CINV/ non-PONV study.
Efter markedsføring Efter markedsføring er der rapporteret om følgende bivirkninger (frekvens ukendt):
Post-marketing experience During post-marketing experience the following side effects have been reported (frequency not known):
Immunsystemet: Hypersensitivitetsreaktioner, herunder anafylaktiske reaktioner.
Skin and subcutaneous tissue disorders: pruritus, rash, urticaria Immune system disorders: hypersensitivity reactions including anaphylactic reactions
Der foreligger ingen specifik information vedrørende behandling af overdosering med EMEND.
No specific information is available on the treatment of overdose with EMEND.
Der er rapporteret om søvnighed og hovedpine hos én patient som indtog 1. 440 mg aprepitant.
Drowsiness and headache were reported in one patient who ingested 1,440 mg of aprepitant.
På grund af aprepitants antiemetiske virkning vil lægemiddelinduceret opkastning sandsynligvis ikke være effektiv.
Because of the antiemetic activity of aprepitant, drug-induced emesis may not be effective.
Antiemetika og kvalmestillende lægemidler.
Antiemetics and antinauseants, ATC code:
I 2 multicenter, randomiserede, dobbeltblindede, aktive komparator- kontrollerede fase- III kliniske undersøgelser med parallelle grupper blev aprepitant sammenlignet med ondansetron til forebyggelse af postoperativ kvalme og opkastning hos 1658 patienter, der fik foretaget åben abdominal kirurgi.
In 2 multicenter, randomized, double-blind, active comparator-controlled, parallel-group phase III clinical studies, aprepitant was compared with ondansetron for the prevention of postoperative nausea and vomiting in 1,658 patients undergoing open abdominal surgery.
Størstedelen af patienterne var kvinder (> 90%), som primært fik foretaget gynækologiske operationer.
The majority of patients were women (> 90%), mainly undergoing gynaecological surgery.
Patienterne blev randomiseret til at få 40 mg aprepitant, 125 mg aprepitant eller 4 mg ondansetron.
Patients were randomized to receive 40 mg aprepitant, 125 mg aprepitant, or 4 mg ondansetron.
Aprepitant blev givet oralt med 50 ml vand 1- 3 timer før anæstesi.
Aprepitant was given orally (PO) with 50 ml of water 1 to 3 hours before anesthesia.
Ondansetron blev givet intravenøst umiddelbart før påbegyndelse af anæstesi.
Ondansetron was given intravenously immediately before induction of anesthesia.
Den antiemetiske virkning af aprepitant blev vurderet i løbet af perioden på 0- 48 timer efter afsluttet kirurgi.
The antiemetic activity of aprepitant was evaluated during the 0 to 48 hour period following the end of surgery.
Resultaterne viser, at en højere procentdel patienter postoperativt oplevede komplet respons (ingen opkastning og ingen erstatningsterapi) med aprepitant 40 mg end med ondansetron 4 mg (nedre grænse for konfidensintervallet er 0, 0, som indikerer borderline signifikans) som beskrevet i Tabel 1.
The results show that a higher percentage of post-surgical patients experienced complete response (no emesis and no use of rescue) with aprepitant 40 mg than with ondansetron 4 mg (lower bound of C. I. is 0.0 indicating borderline significance) as described in Table 1.
6 Tabel 1 Procent af post- operative patienter som responderer pr. behandlingsgruppe Kombinerede resultater fra to fase- III- undersøgelser
6 Table 1 Percent of Post-Operative Patients Responding by Treatment Group Combined Results from 2 Phase III Trials
40 mg PO (N=541)
Aprepitant 40 mg PO (N=541)
4 mg IV (N=526)
Ondansetron 4 mg IV (N=526)
procentpoint (%) § og 95% CI #
Percentage Point Difference (%) § and 95% C. I. #
Komplet respons
(%) n/ m (%)%
(%) n/ m (%) (%)
%) n/ m (%)%
95% CI
95% C. I.
(0- 24 timer) † †
Complete Response (0-24 hours) † †
Komplet repons:
Complete Response:
Ingen opkastning og ingen erstatningsterapi. § Forskel (%) beregnet som aprepitant 40 mg minus ondansetron 4 mg. # Forskel (%) og 95% CI (konfidensinterval) beregnet ved hælp af stratificeret Miettinen- Nurminen metode med anvendelse af Cochran- Mantel- Haenszel vægte.
No emesis and no use of rescue § Difference (%) calculated as Aprepitant 40 mg minus Ondansetron 4 mg # Difference (%) and 95% C. I. calculated using stratified Miettinen-Nurminen method using Cochran-Mantel- Haenszel weights
35, 3 til 66, 3).
The reduction in risk for a vomiting episode over the 0 to 24 hour period with aprepitant 40 mg relative to ondansetron 4 mg was 53.3% (95% C. I.:
Analysen tog udgangspunkt i tidspunktet for, hvornår patienterne fik supplerende behandling.
35.3 to 66.3) in an analysis that censors patients at the time of rescue use.
Absorption Den gennemsnitlige absolutte orale biotilgængelighed for aprepitant er 67% for 80 mg kapslen og 59% for 125 mg kapslen.
Absorption The mean absolute oral bioavailability of aprepitant is 67% for the 80 mg capsule and 59% for the 125 mg capsule.
4 timer (tmax).
The mean peak plasma concentration (Cmax) of aprepitant occurred at approximately 4 hours (tmax).
Efter oral administration af en enkelt 40 mg dosis EMEND under faste var AUC0- ∞ (middel ±SD) 8, 0±2, 1 mikrogram· t/ ml og Cmax var 0, 7±0, 24 mikrogram/ ml.
Following oral administration of a single 40 mg dose of EMEND in the fasted state, the AUC0-∞ (mean ± SD) was 8.0 ± 2.1 microgram x h/ ml and the Cmax was 0.7 ± 0.24 microgram/ ml.
Medianen tmax var 3, 0 timer.
The median tmax was 3.0 hours.
Indtagelse af en dosis på 40 mg sammen med et standard morgenmåltid resulterede i et fald i aprepitants Cmax på 18% men påvirkede ikke AUC.
Concomitant intake of a 40 mg dose with a standard breakfast decreased the aprepitant Cmax by 18% but did not affect AUC.
Distribution Aprepitant er stærkt proteinbundet, med et gennemsnit på 97%.
Distribution Aprepitant is highly protein bound, with a mean of 97%.
66 liter hos mennesker.
The geometric mean apparent volume of distribution at steady state (Vdss) is approximately 66 l in humans.
Metabolisme Aprepitant metaboliseres i stort omfang.
Metabolism Aprepitant undergoes extensive metabolism.
19% af radioaktiviteten i plasma over 72 timer efter en enkelt intravenøs administreret 100 mg dosis af [14C] - fosaprepitant, der er et prodrug for aprepitant, hvilket indikerer en væsentlig tilstedeværelse af metabolitter i plasma.
In healthy young adults, aprepitant accounts for approximately 19% of the radioactivity in plasma over 72 hours following a single intravenous administration 100 mg dose of [14C]-fosaprepitant, a prodrug for aprepitant, indicating a substantial presence of metabolites in the plasma.
Elimination Aprepitant udskilles omdannet i urinen.
Elimination Aprepitant is not excreted unchanged in urine.
Efter en enkelt intravenøst administreret 100 mg dosis af [14C] - fosaprepitant, der er et prodrug for aprepitant til raske personer, genfandtes 57% af radioaktiviteten i urinen og 45% i fæces.
Following a single intravenously administered 100 mg dose of [14C]-fosaprepitant, a prodrug for aprepitant to healthy subjects, 57% of the radioactivity was recovered in urine and 45% in faeces.
60 til 72 ml/ min i det terapeutiske dosisområde.
7 The plasma clearance of aprepitant is dose-dependent, decreasing with increased dose and ranged from approximately 60 to 72 ml/ min in the therapeutic dose range.
9 timer efter administration af en enkelt 40 mg dosis.
The terminal half-life is approximately 9 hours after administration of a single 40 mg dose.
Farmakokinetik hos specielle populationer Ældre:
Pharmacokinetics in special populations Elderly:
Efter oral administration af en enkelt 125 mg dosis aprepitant på dag 1 og 80 mg én gang dagligt på dag 2 til 5 er AUC0- 24 timer for aprepitant 21% højere på dag 1 og 36% højere på dag 5 hos ældre (≥ 65 år) set i forhold til yngre voksne.
Following oral administration of a single 125 mg dose of aprepitant on Day 1 and 80 mg once daily on Days 2 through 5, the AUC0-24hr of aprepitant was 21% higher on Day 1 and 36% higher on Day 5 in elderly (≥ 65 years) relative to younger adults.
Cmax var 10% højere på dag 1 og 24% højere på dag 5 hos ældre i forhold til yngre voksne.
The Cmax was 10% higher on Day 1 and 24% higher on Day 5 in elderly relative to younger adults.
Dosisjustering af EMEND er ikke nødvendig til ældre patienter.
No dosage adjustment for EMEND is necessary in elderly patients.
Efter oral administration af en enkelt 125 mg dosis aprepitant er Cmax for aprepitant 16% højere hos kvinder sammenlignet med mænd.
Following oral administration of a single 125 mg dose of aprepitant, the Cmax for aprepitant is 16% higher in females as compared with males.
Halveringstiden for aprepitant er 25% lavere hos kvinder sammenlignet med mænd, og tmax ses cirka samtidig.
The half-life of aprepitant is 25% lower in females as compared with males and its tmax occurs at approximately the same time.
Dosisjustering af EMEND er ikke nødvendig set i forhold til køn.
No dosage adjustment for EMEND is necessary based on gender.
Mild leverinsufficiens (Child- Pugh klasse A) har ingen klinisk relevant indflydelse på aprepitants farmakokinetik.
Mild hepatic impairment (Child-Pugh class A) does not affect the pharmacokinetics of aprepitant to a clinically relevant extent.
Dosisjustering er ikke nødvendig hos patienter med mild leverinsufficiens.
No dose adjustment is necessary for patients with mild hepatic impairment.
Konklusioner vedrørende indflydelse af moderat leverinsufficiens (Child- Pugh klasse B) på aprepitants farmakokinetik kan ikke udledes af de tilgængelige data.
Conclusions regarding the influence of moderate hepatic impairment (Child-Pugh class B) on aprepitant pharmacokinetics cannot be drawn from available data.
Der er ingen kliniske eller farmakokinetiske data for patienter med alvorlig leverinsufficiens (Child- Pugh klasse C).
There are no clinical or pharmacokinetic data in patients with severe hepatic impairment (Child-Pugh class C).
En enkelt 240 mg dosis aprepitant blev administreret til patienter med alvorlig nyreinsufficiens (CrCl < 30 ml/ min) og til hæmodialysepatienter i det sene stadie (end stage) af nyresygdom.
A single 240 mg dose of aprepitant was administered to patients with severe renal impairment (CrCl < 30 ml/ min) and to patients with end stage renal disease (ESRD) requiring haemodialysis.
Hos patienter med alvorlig nyreinsufficiens faldt AUC0- ∞ for total- aprepitant (ubunden og proteinbundet) med 21% og Cmax faldt med 32%, set i forhold til raske personer.
In patients with severe renal impairment, the AUC0-∞ of total aprepitant (unbound and protein bound) decreased by 21% and Cmax decreased by 32%, relative to healthy subjects.